How is Teriparatide administered?
This describes how Teriparatide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily schedule, generally over ~24 months standard (FDA removed the hard lifetime cap in 2020). Specific dosing is individual and beyond general information, and human evidence for Teriparatide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily
- Cycle length: ~24 months standard (FDA removed the hard lifetime cap in 2020)
- Half-life: ~1 hour
References
- Effect of Teriparatide on the risk of fractures in postmenopausal women with osteoporosis — Neer RM et al., NEJM, 2001
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial — Kendler DL, Marin F, Geusens P, et al. — The Lancet, 2018
- FORTEO (teriparatide) injection — FDA Prescribing Information — FDA / DailyMed (Eli Lilly and Company)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Teriparatide
Last updated 2026-06-15.